Insights & Resources

Life sciences companies often overlook SOX in IPO prep. Discover how early action and targeted strategies can strengthen investor confidence.

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Discover how outsourcing in pharmaceutical manufacturing enhances quality, ensures compliance and mitigates risks in a rapidly evolving industry.

New York’s business interruption law introduced new stand-alone coverage opportunities, providing businesses options for tailored protection.

Weaver has developed carbon accounting processes to determine our carbon footprint across Scope 1 and Scope 2 emissions.

Microsoft has reformed the calculation of its supply-chain emissions through innovative accounting to align with its carbon-negative 2030 goals. Learn more here.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

These essential estate planning strategies will help develop a robust plan to protect your assets, reduce taxes and ensure more for your heirs.

Managing revenue cycles is an important aspect of modern hospital operations. Defined business processes and strong internal controls are the keys to optimization.

Weaver’s second quarterly Accounting and SEC Update of 2024 covered stock compensation and other standards updates, filer status assessments and recent SEC/ PCAOB enforcement actions.